Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30111760 | 0.89 | EPHB4 (0.38) | GRM2SIGMAR1MCHR1GRIN2B | |
| SCHEMBL24034800 | 0.89 | EPHB4 (0.38) | GRM2SIGMAR1MCHR1GRIN2B | |
| SCHEMBL30111754 | 0.88 | GRM2 (0.37) | GRM2SIGMAR1MCHR1GRIN2BCYP2C9 | |
| SCHEMBL26098995 | 0.88 | GRM2 (0.37) | GRM2SIGMAR1MCHR1GRIN2BCYP2C9 | |
| SCHEMBL24034797 | 0.85 | RIPK3 (0.39) | GRM2SIGMAR1MCHR1 | |
| SCHEMBL24034801 | 0.85 | IDO1 (0.37) | GRM2SIGMAR1MCHR1GRIN2B | |
| SCHEMBL30111748 | 0.84 | GRM2 (0.36) | GRM2SIGMAR1MCHR1GRIN2B | |
| SCHEMBL30111725 | 0.84 | GRM2 (0.35) | GRM2SIGMAR1MCHR1GRIN2BCYP2C9 | |
| SCHEMBL24034906 | 0.84 | GRM2 (0.36) | GRM2SIGMAR1MCHR1GRIN2B | |
| SCHEMBL24034607 | 0.84 | GRM2 (0.35) | GRM2SIGMAR1MCHR1GRIN2BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021228795-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-18 | — | — | WO | disclosed |